With the increase in the medical level, the improvement of adverse drug reaction(ADR) monitoring systems, and the enhancement of public awareness of safe medication, drugsafety incidents have been frequently reported. Drug-induced liver injury(DILI), especially liverinjury attributed to herbal and dietary supplements(HDS), has globally attracted high attention, bringing great threats and severe challenges to the people for drugsafety management such as clinical medication and medical supervision. Consensus on drug-induced liver injury had been published by the Council for International Organizations of Medical Sciences(CIOMS) in 2020. In this consensus, liverinjury attributed to HDS was included in a special chapter for the first time. The hot topics, including the definition of HDS-induced liverinjury, epidemiological history, potential risk factors, collection of related risk signals, causalityassessment, risk prevention, control and management were discussed from a global perspective. Based on the previous works, some experts from China were invited by CIOMS to undertake the compilation of this chapter. Meanwhile, a new causality assessment in DILI based on the integrated evidence chain(iEC) method was widely recognized by experts in China and abroad, and was recommended by this consensus. This paper briefly introduced the main contents, background, and characteristics of the Consensus on drug-induced liver injury. Significantly, a brief interpretation was illustrated to analyze the special highlights of Chapter 8, "Liverinjury attributed to HDS", so as to provide practical references for the medical staff and the researcherswho worked on either Chinese or Western medicine in China.